The FDA declined to approve lung cancer drug ivonescimab
The FDA declined to approve ivonescimab, a lung cancer drug first developed by China’s Akeso and being developed outside China by Summit Therapeutics, after a late-stage trial showed it delayed disease progression but did not demonstrate a statistically significant overall-survival benefit. The agency said the progression benefit alone did not establish a positive benefit-risk balance for approval.
Get The Augerton Digest by email.
Bloomberg said Summit sought authorization for the drug to treat a narrow group of patients with advanced non-small cell lung cancer who had previously received EGFR-targeting drugs. Reuters reported that, when combined with chemotherapy, ivonescimab reduced the risk of progression or death by 48% compared with chemotherapy alone.
Summit has argued that longer follow-up supports the treatment, citing revised data showing lower death rates among Western and Asian patient subgroups, The News International reported.
Was this story useful?
What was the main problem? (optional)
Reporting behind this story
- Bloomberg — US FDA Rejects Summit’s China-Originated Lung Cancer Drug
- Mezha — FDA declines to approve Summit Therapeutics’ lung cancer drug after trial misses survival goal
- The News International — US FDA rejects Summit’s lung cancer drug after trial fails to meet survival goal
- UA News — FDA declines to approve ivonescimab for lung cancer — STAT News
- fiercepharma.com — FDA rejects Summit’s PD-1xVEGF ivonescimab in NSCLC